NCT03964805 (EmbryOx) is a NA clinical trial of 20% oxygen in Infertility, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT03964805?

NCT03964805 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT03964805?

Interventions in NCT03964805: 20% oxygen, 5% oxygen, 20 % and 5 % oxygen.

What condition does NCT03964805 study?

NCT03964805 studies Infertility, Embryo Culture, Hypoxia.

Is NCT03964805 still recruiting?

NCT03964805 is currently completed. Last updated 28 May 2019.

Last reviewed 2019-05-28 · How we verify

NCT03964805: EmbryOx

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oxygen Tension on Human Embryonic Development

Completed NA Last updated 28 May 2019

What this trial tests

NA trial testing 20% oxygen in Infertility in 773 participants. Completed in 1 December 2018.

Timeline

1 September 2016

Primary endpoint
6 September 2018

1 December 2018

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	773
Start date	1 September 2016
Primary completion	6 September 2018
Estimated completion	1 December 2018

Drugs / interventions tested

20% oxygen
5% oxygen
20 % and 5 % oxygen

Conditions studied

Infertility — all drugs for Infertility →
Embryo Culture — all drugs for Embryo Culture →
Hypoxia — all drugs for Hypoxia →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 18 to 39, any sex, with Infertility or Embryo Culture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In mammals, uterine environment is at low oxygen concentration (2-8% O2). Thus, human embryo culture under low O2 tension (5%) is now recommended by European Society of Human Reproduction and Embryology (ESHRE) revised guidelines for good practices in in vitro fertilization (IVF) labs. Indeed, hypoxia seems to improve embryo quality at cleavage and blastocyst stages, presumably by reducing damages of oxidative stress (OS). Nevertheless, recent meta-analyses concluded only with a low evidence to a superiority of hypoxia on IVF/ICSI outcomes. Furthermore, a study on mouse embryos suggested a negative impact of OS only at cleavage stage. The aim of the present prospective randomized study was to investigate this hypothesis for the first time in human embryos.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Impact of oxygen tension according to embryo stage of development: a prospective randomized study.
Herbemont C, Labrosse J, Bennani-Smires B, Cedrin-Durnerin I, et al · · 2021 · cited 9× · PMID 34785697 · DOI 10.1038/s41598-021-01488-9

Verify or expand the search:

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03964805 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 28 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03964805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing